NextCure (NASDAQ:NXTC) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of NextCure (NASDAQ:NXTC) from a strong sell rating to a hold rating in a research report released on Thursday morning,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research report on Monday, April 27th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $23.00.

NextCure Trading Down 6.7%

Shares of NASDAQ:NXTC opened at $2.08 on Thursday. The stock has a market capitalization of $7.51 million, a P/E ratio of -0.12 and a beta of 1.30. NextCure has a 1-year low of $2.00 and a 1-year high of $15.74. The business has a 50-day moving average price of $8.56 and a two-hundred day moving average price of $11.00.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping the consensus estimate of ($2.10) by $0.23. As a group, equities analysts predict that NextCure will post -7.9 EPS for the current year.

Hedge Funds Weigh In On NextCure

Several institutional investors have recently modified their holdings of NXTC. Marshall Wace LLP acquired a new position in shares of NextCure during the 4th quarter worth about $160,000. Millennium Management LLC acquired a new position in shares of NextCure during the 4th quarter worth about $185,000. Geode Capital Management LLC grew its position in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the period. Cable Car Capital LP grew its position in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after buying an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after buying an additional 5,300 shares during the period. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.